- Home
- ME vs INMB Comparison
ME vs INMB Comparison
Compare ME & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- INMB
- Stock Information
- Founded
- ME 2006
- INMB 2015
- Country
- ME United States
- INMB United States
- Employees
- ME N/A
- INMB 17
- Industry
- ME Precision Instruments
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- ME Health Care
- INMB Health Care
- Exchange
- ME Nasdaq
- INMB Nasdaq
- Market Cap
- ME 113.9M
- INMB 108.0M
- IPO Year
- ME N/A
- INMB 2019
- Fundamental
- Price
- ME $3.11
- INMB $4.87
- Analyst Decision
- ME Hold
- INMB Strong Buy
- Analyst Count
- ME 1
- INMB 2
- Target Price
- ME $9.40
- INMB $21.00
- AVG Volume (30 Days)
- ME 453.1K
- INMB 239.3K
- Earning Date
- ME 11-12-2024
- INMB 10-31-2024
- Dividend Yield
- ME N/A
- INMB N/A
- EPS Growth
- ME N/A
- INMB N/A
- EPS
- ME N/A
- INMB N/A
- Revenue
- ME $193,260,000.00
- INMB $42,000.00
- Revenue This Year
- ME $21.93
- INMB N/A
- Revenue Next Year
- ME $17.31
- INMB N/A
- P/E Ratio
- ME N/A
- INMB N/A
- Revenue Growth
- ME N/A
- INMB N/A
- 52 Week Low
- ME $2.66
- INMB $4.45
- 52 Week High
- ME $20.40
- INMB $14.74
- Technical
- Relative Strength Index (RSI)
- ME 30.62
- INMB 39.31
- Support Level
- ME $2.66
- INMB $4.45
- Resistance Level
- ME $3.58
- INMB $6.26
- Average True Range (ATR)
- ME 0.45
- INMB 0.31
- MACD
- ME -0.08
- INMB -0.14
- Stochastic Oscillator
- ME 16.90
- INMB 19.63
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.